nodes	percent_of_prediction	percent_of_DWPC	metapath
Drospirenone—PTGS2—muscle cancer	0.894	1	CbGaD
Drospirenone—AR—scrotum—muscle cancer	0.0253	0.255	CbGeAlD
Drospirenone—BCHE—diaphragm—muscle cancer	0.0171	0.172	CbGeAlD
Drospirenone—PTGS2—hindlimb—muscle cancer	0.00541	0.0545	CbGeAlD
Drospirenone—PTGS2—appendage—muscle cancer	0.00464	0.0467	CbGeAlD
Drospirenone—NR3C2—smooth muscle tissue—muscle cancer	0.00261	0.0263	CbGeAlD
Drospirenone—NR3C2—renal system—muscle cancer	0.00251	0.0253	CbGeAlD
Drospirenone—PGR—smooth muscle tissue—muscle cancer	0.00243	0.0244	CbGeAlD
Drospirenone—NR3C2—cardiac atrium—muscle cancer	0.00225	0.0226	CbGeAlD
Drospirenone—NR3C2—tendon—muscle cancer	0.00196	0.0197	CbGeAlD
Drospirenone—AR—smooth muscle tissue—muscle cancer	0.00193	0.0195	CbGeAlD
Drospirenone—AR—renal system—muscle cancer	0.00186	0.0187	CbGeAlD
Drospirenone—NR3C2—vagina—muscle cancer	0.00182	0.0183	CbGeAlD
Drospirenone—PGR—vagina—muscle cancer	0.00169	0.017	CbGeAlD
Drospirenone—NR3C2—head—muscle cancer	0.00168	0.0169	CbGeAlD
Drospirenone—AR—cardiac atrium—muscle cancer	0.00167	0.0168	CbGeAlD
Drospirenone—NR3C2—testis—muscle cancer	0.00162	0.0163	CbGeAlD
Drospirenone—BCHE—smooth muscle tissue—muscle cancer	0.00157	0.0158	CbGeAlD
Drospirenone—PGR—head—muscle cancer	0.00156	0.0157	CbGeAlD
Drospirenone—PTGS2—embryo—muscle cancer	0.00154	0.0155	CbGeAlD
Drospirenone—PGR—testis—muscle cancer	0.00151	0.0152	CbGeAlD
Drospirenone—AR—tendon—muscle cancer	0.00145	0.0146	CbGeAlD
Drospirenone—BCHE—cardiac atrium—muscle cancer	0.00136	0.0136	CbGeAlD
Drospirenone—AR—vagina—muscle cancer	0.00135	0.0136	CbGeAlD
Drospirenone—AR—head—muscle cancer	0.00125	0.0125	CbGeAlD
Drospirenone—PTGS2—smooth muscle tissue—muscle cancer	0.00121	0.0122	CbGeAlD
Drospirenone—AR—testis—muscle cancer	0.0012	0.0121	CbGeAlD
Drospirenone—PTGS2—renal system—muscle cancer	0.00117	0.0117	CbGeAlD
Drospirenone—BCHE—bone marrow—muscle cancer	0.00115	0.0115	CbGeAlD
Drospirenone—BCHE—vagina—muscle cancer	0.0011	0.011	CbGeAlD
Drospirenone—BCHE—head—muscle cancer	0.00101	0.0102	CbGeAlD
Drospirenone—BCHE—testis—muscle cancer	0.000979	0.00985	CbGeAlD
Drospirenone—PTGS2—tendon—muscle cancer	0.000911	0.00916	CbGeAlD
Drospirenone—PTGS2—bone marrow—muscle cancer	0.000882	0.00888	CbGeAlD
Drospirenone—PTGS2—vagina—muscle cancer	0.000845	0.0085	CbGeAlD
Drospirenone—Cerebral infarction—Vincristine—muscle cancer	0.000826	0.129	CcSEcCtD
Drospirenone—PTGS2—head—muscle cancer	0.000781	0.00786	CbGeAlD
Drospirenone—Thromboembolic event—Methotrexate—muscle cancer	0.000485	0.0755	CcSEcCtD
Drospirenone—Venous thromboembolism—Doxorubicin—muscle cancer	0.000385	0.0599	CcSEcCtD
Drospirenone—Loss of libido—Methotrexate—muscle cancer	0.000283	0.0441	CcSEcCtD
Drospirenone—Embolism venous—Doxorubicin—muscle cancer	0.000224	0.0349	CcSEcCtD
Drospirenone—Embolism—Methotrexate—muscle cancer	0.000204	0.0317	CcSEcCtD
Drospirenone—Embolism—Doxorubicin—muscle cancer	0.000176	0.0274	CcSEcCtD
Drospirenone—Thrombosis—Doxorubicin—muscle cancer	0.00016	0.0249	CcSEcCtD
Drospirenone—Depression—Vincristine—muscle cancer	0.00015	0.0234	CcSEcCtD
Drospirenone—Acute coronary syndrome—Vincristine—muscle cancer	0.000148	0.0231	CcSEcCtD
Drospirenone—Myocardial infarction—Vincristine—muscle cancer	0.000148	0.023	CcSEcCtD
Drospirenone—Erythema multiforme—Dactinomycin—muscle cancer	0.000143	0.0223	CcSEcCtD
Drospirenone—Breast pain—Doxorubicin—muscle cancer	0.00013	0.0202	CcSEcCtD
Drospirenone—Angiopathy—Vincristine—muscle cancer	0.000123	0.0191	CcSEcCtD
Drospirenone—Acute coronary syndrome—Etoposide—muscle cancer	0.00012	0.0187	CcSEcCtD
Drospirenone—Myocardial infarction—Etoposide—muscle cancer	0.00012	0.0186	CcSEcCtD
Drospirenone—Mental disorder—Vincristine—muscle cancer	0.000118	0.0184	CcSEcCtD
Drospirenone—Erythema multiforme—Etoposide—muscle cancer	0.000104	0.0161	CcSEcCtD
Drospirenone—Angiopathy—Etoposide—muscle cancer	9.94e-05	0.0155	CcSEcCtD
Drospirenone—Cerebrovascular accident—Methotrexate—muscle cancer	9.68e-05	0.0151	CcSEcCtD
Drospirenone—Nervous system disorder—Vincristine—muscle cancer	9.42e-05	0.0147	CcSEcCtD
Drospirenone—Mood swings—Methotrexate—muscle cancer	8.98e-05	0.014	CcSEcCtD
Drospirenone—Breast disorder—Methotrexate—muscle cancer	8.57e-05	0.0133	CcSEcCtD
Drospirenone—Cerebrovascular accident—Doxorubicin—muscle cancer	8.38e-05	0.013	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Vincristine—muscle cancer	8.29e-05	0.0129	CcSEcCtD
Drospirenone—Migraine—Doxorubicin—muscle cancer	8.08e-05	0.0126	CcSEcCtD
Drospirenone—Affect lability—Doxorubicin—muscle cancer	8.08e-05	0.0126	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	8.06e-05	0.0126	CcSEcCtD
Drospirenone—Mood swings—Doxorubicin—muscle cancer	7.78e-05	0.0121	CcSEcCtD
Drospirenone—Skin disorder—Etoposide—muscle cancer	7.56e-05	0.0118	CcSEcCtD
Drospirenone—Breast disorder—Doxorubicin—muscle cancer	7.42e-05	0.0116	CcSEcCtD
Drospirenone—Depression—Methotrexate—muscle cancer	7.29e-05	0.0113	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Etoposide—muscle cancer	6.72e-05	0.0105	CcSEcCtD
Drospirenone—Haemoglobin—Methotrexate—muscle cancer	6.59e-05	0.0103	CcSEcCtD
Drospirenone—Haemorrhage—Methotrexate—muscle cancer	6.56e-05	0.0102	CcSEcCtD
Drospirenone—Nausea—Dactinomycin—muscle cancer	6.39e-05	0.00995	CcSEcCtD
Drospirenone—Erythema multiforme—Methotrexate—muscle cancer	6.2e-05	0.00966	CcSEcCtD
Drospirenone—Angiopathy—Methotrexate—muscle cancer	5.95e-05	0.00927	CcSEcCtD
Drospirenone—Mental disorder—Methotrexate—muscle cancer	5.75e-05	0.00895	CcSEcCtD
Drospirenone—Haemoglobin—Doxorubicin—muscle cancer	5.71e-05	0.00889	CcSEcCtD
Drospirenone—Nausea—Vincristine—muscle cancer	5.71e-05	0.00889	CcSEcCtD
Drospirenone—Haemorrhage—Doxorubicin—muscle cancer	5.68e-05	0.00885	CcSEcCtD
Drospirenone—Erythema multiforme—Doxorubicin—muscle cancer	5.37e-05	0.00836	CcSEcCtD
Drospirenone—Angiopathy—Doxorubicin—muscle cancer	5.15e-05	0.00803	CcSEcCtD
Drospirenone—Mental disorder—Doxorubicin—muscle cancer	4.98e-05	0.00775	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	4.83e-05	0.00752	CcSEcCtD
Drospirenone—Nausea—Etoposide—muscle cancer	4.62e-05	0.0072	CcSEcCtD
Drospirenone—Nervous system disorder—Methotrexate—muscle cancer	4.57e-05	0.00712	CcSEcCtD
Drospirenone—Skin disorder—Methotrexate—muscle cancer	4.53e-05	0.00705	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	4.18e-05	0.00651	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Methotrexate—muscle cancer	4.02e-05	0.00627	CcSEcCtD
Drospirenone—Nervous system disorder—Doxorubicin—muscle cancer	3.96e-05	0.00616	CcSEcCtD
Drospirenone—Skin disorder—Doxorubicin—muscle cancer	3.92e-05	0.0061	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Doxorubicin—muscle cancer	3.48e-05	0.00543	CcSEcCtD
Drospirenone—Nausea—Methotrexate—muscle cancer	2.77e-05	0.00431	CcSEcCtD
Drospirenone—Nausea—Doxorubicin—muscle cancer	2.4e-05	0.00373	CcSEcCtD
